Thank you Madge for posting this. I am an RN CDE working with the study, called DEFEND-2. It's for people newly diagnosed with type 1, ages 12-45 years old, within the first 90 days of diagnosis. The reason one needs to get in the study early on is the time where you may still have beta cells, the cells that produce insulin. The study drug, otelixizumab, is being investigated to see if it will stop the autoimmune attack on the beta cells, and protect the beta cells from further attack. If so, this will mean one needs to use less insulin to get to their target numbers of blood sugar and A1C. This could mean less blood sugar swings, less complications, and better quality of life. Yes, this is an international study. Learn more at http://defendagainstdiabetes.com/.